SCHEMBL14217337

SCHEMBL14217337

CCCc1ccc(N2CCC(N)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 2/20 0.51
L3MBTL3 Q96JM7 10/20 0.44
L3MBTL1 Q9Y468 7/20 0.44
MBTD1 Q05BQ5 1/20 0.44
TP53BP1 Q12888 1/20 0.44
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MGLL Q99685 1/20 0.42
S1PR1 P21453 1/20 0.40
DPP4 P27487 2/20 0.39
HTR7 P34969 2/20 0.39
HTR6 P50406 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
RAD52 P43351 1/20 0.39
GFER P55789 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8840531 0.90 SPHK1 (0.60) SPHK1L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL22144419 0.86 KDM4E (0.49) SPHK1L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL19567594 0.84 USP2 (0.51) L3MBTL3L3MBTL1MBTD1TP53BP1MAOA
SCHEMBL22856413 0.83 MAOA (0.47) L3MBTL3L3MBTL1MBTD1TP53BP1MAOA
SCHEMBL8730118 0.83 L3MBTL3 (0.44) SPHK1L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL25833691 0.81 MAOB (0.52) L3MBTL3L3MBTL1MBTD1TP53BP1MAOA
SCHEMBL28853366 0.80 L3MBTL3 (0.42) SPHK1L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL14393584 0.80 HTR2A (0.48) SPHK1L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL27249154 0.80 CHKA (0.51) L3MBTL3L3MBTL1MGLLS1PR1HTR7
SCHEMBL8349588 0.80 CHKA (0.51) L3MBTL3L3MBTL1MBTD1TP53BP1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120309760-A1 PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2012-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309760-A1 PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT GRIK5, GRK5, KCNJ5 SPHK1 1071/4885L3MBTL3 4147/4885L3MBTL1 3806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.